ENO2 and neoplasm: Fortunately, the patient experienced substantial pain relief, and tumor markers decreased significantly from pre-treatment levels (cytokeratin 19 fragment and neuron-specific enolase levels dropped to 24.90 ng/ml and 23.20 ng/ml, respectively) (Figure 2B).